Form 4: Bolt Biotherapeutics Director Reprices Options Lower

Kathleen Laporte, a director at Bolt Biotherapeutics, exchanged existing stock options for new options with significantly lower exercise prices on December 12, 2025.

Summary

• Kathleen Laporte, a Director of Bolt Biotherapeutics, Inc. (BOLT), engaged in a series of option exchanges on December 12, 2025.
• Existing stock options with higher exercise prices, originally granted between December 29, 2020, and May 27, 2025, were cancelled.
• In exchange, new stock options for the same number of underlying shares were granted with a significantly lower exercise price of $5.44 per share.
• The cancelled options had exercise prices ranging from $6.40 to $88.20 per share.
• A total of 8,592 shares underlying options were repriced.
• All new options, except for one grant of 1,100 shares, are fully vested and exercisable.
• The new option for 1,100 shares (expiring May 26, 2035) will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders, subject to continuous service, with full vesting upon a change in control of the Issuer.

Sentiment

Score: 3

Explanation: The option repricing typically occurs when the stock price has fallen significantly below previous grant prices, indicating poor past performance and potential shareholder value destruction. While it re-incentivizes the director, it is generally viewed negatively by investors and corporate governance advocates.

Positives

• The director, Kathleen Laporte, received new stock options with a substantially lower exercise price of $5.44, which could increase her incentive and potential for future gains.
• Most of the newly granted options are fully vested and immediately exercisable, providing immediate liquidity potential for the director.

Negatives

• The repricing of options from significantly higher strike prices (up to $88.20) to $5.44 implies a substantial decline in the company's stock price since the original grant dates, indicating past underperformance.
• Option repricing can be viewed negatively by shareholders as it effectively gives directors a 'do-over' on underwater options, potentially diluting shareholder value and insulating them from downside risk.

Risks

• The transaction implies a significant risk of past stock price underperformance, as the original options were deeply out-of-the-money, necessitating the repricing.
• Potential for negative investor perception regarding corporate governance and compensation practices, as option repricing is often criticized for misaligning management incentives with shareholder interests.
• Risk of shareholder dilution if the repriced options are exercised, particularly if the company's stock price recovers.

Future Outlook

One new option grant for 1,100 shares has a future vesting schedule, contingent on continuous service until May 27, 2026, or the day prior to the next annual meeting, with full vesting upon a change in control. This indicates a forward-looking incentive for the director's continued involvement.

Industry Context

Option repricing, while not uncommon in industries experiencing significant stock price volatility like biotechnology, often signals challenges in retaining and incentivizing key personnel when original equity grants are underwater. It reflects a company's effort to re-align incentives following a period of stock underperformance.

Comparison to Industry Standards

• Repricing of underwater stock options is generally viewed negatively by corporate governance experts and institutional investors, such as those guided by proxy advisory firms like Institutional Shareholder Services (ISS) and Glass Lewis.
• These practices are often seen as misaligning management incentives with shareholder interests, as they effectively insulate executives and directors from the downside risk of stock price declines that shareholders bear.
• While specific comparable companies are not mentioned in the filing, such actions typically raise concerns about accountability and the effectiveness of compensation committees in adhering to best practices for executive and director compensation.

Corporate Governance

Related Party Transactions

• The transaction involves a director of Bolt Biotherapeutics, Kathleen Laporte, exchanging stock options with the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for dilution from the repriced options and a negative signal regarding past stock performance and corporate governance practices.
• Director (Kathleen Laporte): Significantly increased incentive and potential for future gains due to the substantially lower exercise price of the new options.
• Employees: The repricing could set a precedent for other employee options if the company's stock continues to underperform, potentially impacting broader employee morale and retention strategies.

Next Steps

• Monitoring the vesting of the 1,100 new options granted to Kathleen Laporte, which is contingent on her continuous service until May 27, 2026, or the day prior to the next annual meeting.

Key Dates

Recommendation

The option repricing suggests significant past stock underperformance, which is a negative signal for investors. However, without a broader financial context or additional company news, a definitive 'sell' recommendation is not warranted. Investors should hold and monitor future performance, particularly how the company addresses its stock valuation and broader strategic initiatives.

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, stock options, option repricing, director compensation, equity compensation, insider transaction, corporate governance